Profound Medical (TSE:PRN) has released an update.
Profound Medical Corp. has reported a modest revenue increase to $1.91 million in Q1 2024, up 3% from the previous year, with strong growth in the TULSA-PRO systems installed base, anticipating further expansion. The company has initiated full-year revenue guidance, signalling confidence in the TULSA procedure’s adoption, and is awaiting FDA review for its latest TULSA AI module, with significant CMS reimbursement developments expected later in the year.
For further insights into TSE:PRN stock, check out TipRanks’ Stock Analysis page.
